Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Mar 1:172:9-13.
doi: 10.1016/j.drugalcdep.2016.11.030. Epub 2016 Dec 14.

Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers

Shanna Babalonis  1 , Margaret Haney  2 , Robert J Malcolm  3 , Michelle R Lofwall  4 , Victoria R Votaw  5 , Steven Sparenborg  6 , Sharon L Walsh  4
Affiliations
Randomized Controlled Trial

Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers

Shanna Babalonis et al. Drug Alcohol Depend. .

Abstract

Background: Cannabidiol (CBD) is a naturally occurring constituent of the marijuana plant. In the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is currently being explored for numerous disease conditions (e.g., pain, epilepsy, cancer, various drug dependencies). However, CBD remains a Schedule I drug on the U.S. Controlled Substances Act (CSA). Despite its status, there are no well-controlled data available regarding its abuse liability.

Methods: Healthy, frequent marijuana users (n=31) were enrolled in this within subject, randomized, placebo-controlled, double-blind, multisite study that administered oral cannabidiol (0, 200, 400, 800mg) alone and in combination with smoked marijuana (0.01%, 5.3-5.8% THC). Participants received one dose combination across 8 once-weekly outpatient sessions (7.5h). The primary findings on the drug interaction effects were previously reported (Haney et al., 2016). The present study is a secondary analysis of the data to examine the abuse liability profile of oral cannabidiol (200, 400, 800mg) in comparison to oral placebo and active smoked marijuana (5.3-5.8% THC).

Results: Active marijuana reliably produced abuse-related subjective effects (e.g., high) (p<0.05). However, CBD was placebo-like on all measures collected (p>0.05).

Conclusions: Overall, CBD did not display any signals of abuse liability at the doses tested and these data may help inform U.S. regulatory decisions regarding CBD schedule on the CSA.

Keywords: Abuse liability; CBD; Cannabidiol; Human; Smoked marijuana.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Peak ratings of the visual analog items “I feel high” (left panel) and “I feel a good drug effect” (middle panel) and estimates from a marijuana street value assessment (right panel) presented as a function of dose condition (n=31, ±SEM). Peak effect analyses detected a main effect of active marijuana (5.3-5.8% THC) on each measure. Tukey's post-hoc tests indicated that 1) active CBD doses were not significantly different from placebo CBD (p>.05) and 2) active marijuana condition was significantly different from each of the CBD dose conditions (0, 200, 400, 800 mg, collected under inactive marijuana [0.01% THC] conditions), as indicated by the asterisk (p<.05). The abbreviations on the graphs are as follows: MJ=active marijuana/placebo CBD, CBD 0= 0 mg CBD/placebo marijuana, CBD 200 = 200 mg CBD/placebo marijuana, CBD 400 = 400 mg CBD/placebo marijuana, CBD 800 = 800 mg CBD/placebo marijuana.
See this image and copyright information in PMC

References

    1. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE, Martin-Santos R, Hallak JE, Zuardi AW, Crippa JA. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219–1226. - PMC - PubMed
    1. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, CM OC, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764–774. - PMC - PubMed
    1. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845–852. - PMC - PubMed
    1. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40:701–708. - PubMed
    1. Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend. 2009;103:107–113. - PMC - PubMed

Publication types